ACVD home

Vaccine research requires a multi-disciplinary strategy which involves expertise in basic and applied immunology, pathogenesis, molecular and structural biology with preclinical and clinical trials methodology.

The Queensland Insitute of Medical Research (QIMR) encompasses this varied expertise within a single institution and the ACVD harnesses this to advance the science of vaccine development.

New collaborative links with biotech industry

Second collaborative agreement with
Henderson Morley
The ACVD has signed another agreement with Henderson-Morley plc for the development of EBV vaccine. The collaborative project will use an EBV polyepitope antigen developed by the team at ACVD, incorporated into the PREPS and L-particles delivery vector, to produce a new vaccine candidate targeted at numerous strains of EBV.
More information

QIMR and Merck initiate vaccine research collaboration
In August 2007, researchers from the ACVD at the Queensland Institute of Medical Research (QIMR) and Merck & Co., Inc., a global pharmaceutical company, have entered into a research collaboration to develop a vaccine to combat Group A Streptococcus (GAS).
More information

Collaborative agreement between Australian Centre for Vaccine Development and Henderson Morley plcd
The Directors of Henderson Morley plc (“Henderson Morley” or “the Company”) the drug discovery company, are pleased to announce the signature of a material transfer and collaborative research agreement with the Australian Centre for Vaccine Development (“ACVD”), part of the Queensland Institute of Medical Research.
More information

	Vaccine research requires a multi-disciplinary strategy which involves expertise in basic and applied immunology, pathogenesis, molecular and structural biology with preclinical and clinical trials methodology. The Queensland Insitute of Medical Research (QIMR) encompasses this varied expertise within a single institution and the ACVD harnesses this to advance the science of vaccine development. New collaborative links with biotech industry Second collaborative agreement with Henderson Morley The ACVD has signed another agreement with Henderson-Morley plc for the development of EBV vaccine. The collaborative project will use an EBV polyepitope antigen developed by the team at ACVD, incorporated into the PREPS and L-particles delivery vector, to produce a new vaccine candidate targeted at numerous strains of EBV. More information QIMR and Merck initiate vaccine research collaboration In August 2007, researchers from the ACVD at the Queensland Institute of Medical Research (QIMR) and Merck & Co., Inc., a global pharmaceutical company, have entered into a research collaboration to develop a vaccine to combat Group A Streptococcus (GAS). More information Collaborative agreement between Australian Centre for Vaccine Development and Henderson Morley plcd The Directors of Henderson Morley plc (“Henderson Morley” or “the Company”) the drug discovery company, are pleased to announce the signature of a material transfer and collaborative research agreement with the Australian Centre for Vaccine Development (“ACVD”), part of the Queensland Institute of Medical Research. More information
		Tellam J, Smith C, Rist M, Webb N, Cooper L, Vuocolo T, Connolly G, Tscharke DC, Devoy MP and Khanna R. Regulation of protein translation through mRNA structure influences MHC class I locading and T cell recognition. PNAS 205 (27) 9319-9324. Download PDF Elliott SL, Suhrbier A, Miles JJ, Lawrence G, Pye SJ, Le TT, Rosenstengel A, Nguyen T, Allworth A, Burrows SR, Cox J, Pye D, Moss DJ, Bharadwaj M. Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis. J Virol. 2008 Feb;82(3):1448-57. Download PDF Wynn KK, Marland Z, Cooper L, Silins SL, Gras S, Archbold JK, Tynan FE, Miles JJ, McCluskey J, Burrows SR, Rossjohn J, Khanna R. Impact of clonal competition for peptide-MHC complexes on the CD8+ T-cell repertoire selection in a persistent viral infection. Blood 2008 April; 111:4283-4292. Download PDF Pinzon-Charry A and F Good M F. Malaria vaccines: the case for a whole-organism approach. Expert Opin.Biol.Ther. 8(4):441-448, 2008. Download PDF McManus DP and Loukas A. Current Status of Vaccines for Schistosomiasis. Clin. Microbiol. Rev. 21(1):225-242,, 2008. Download PDF




























			DR DENISE DOOLAN Head of the newly established Translational and Vaccine Immunology Laboratory at QIMR.
World Vaccine Congress 2008 13-15 October 2008 Intercontinental, Sydney Brochure Registration Form